Riding the pepTIDE — The Daily Wire on Therapeutic Peptides

An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.

Topic Sections

  • Top Shots — The most significant peptide and longevity stories ranked by overall editorial score
  • Research Signals — High-credibility scientific findings from journals, preprints, and clinical sources
  • Healing & Recovery — Tissue repair, injury recovery, and gut healing peptides including BPC-157 and TB-500
  • Growth Hormone Wire — Growth hormone secretagogues, peptide stacks, and GH axis research including Ipamorelin, CJC-1295, and MK-677
  • Metabolic & GLP-1 — Metabolic health, insulin sensitivity, and GLP-1 receptor agonist research including semaglutide and tirzepatide
  • Cognitive / Nootropic — Peptides targeting brain function, memory, neuroprotection, and cognitive enhancement
  • Skin & Cosmetic — Skin repair, anti-aging, collagen synthesis, and cosmetic peptide research including GHK-Cu and matrixyl
  • Reddit Finds — Community-sourced discussions, self-experimentation reports, and protocol threads from peptide communities
  • Contrarian Takes — Alternative viewpoints, dissenting research, and perspectives that challenge mainstream peptide narratives
  • Skeptic's Corner — Hype debunking, low-evidence alerts, and critical analysis of overstated peptide claims

Browse by Filter

  • Newest — Latest peptide and longevity stories
  • Most Credible — Highest credibility-scored stories
  • Most Edgy — High-novelty, unconventional findings
  • Most Discussed — Trending community discussions
  • Most Actionable — Direct applicability to daily health protocols
  • Lowest Risk — Stories with strong evidence, low hype
  • Research Only — Peer-reviewed and preprint studies
  • Reddit Only — Community discussion and anecdote
  • GLP-1 / Metabolic — Semaglutide, tirzepatide, and metabolic peptides
  • Healing / Recovery — BPC-157, TB-500, and repair protocols

More

  • About Riding the pepTIDE
  • Health Disclaimer
  • Submit a Source
  • Contact

Mounjaro at 15 mg, No Pounds Lost — Others Experiencing This?

Someone on a forum says they restarted tirzepatide (brand name Mounjaro) after pregnancy. The first time it helped them lose 50 pounds, but after having a baby they regained the weight. They restarted the drug, were titrated from 12.5 mg to 15 mg, and after about 12 weeks at 15 mg they say they haven’t lost any weight despite being active with a baby and walking about 7,000 steps a day. They’re asking if anyone else had the same experience. Tirzepatide is a prescription medication sold as Mounjaro. It’s a synthetic peptide (a small protein-like drug) that acts on hormone receptors involved in appetite and blood sugar control. In plain language: it tricks parts of your body into feeling fuller and can slow digestion, which often leads people to eat less and lose weight. It’s not a stimulant or a diet pill — it’s more like a hormonal nudge that changes hunger and how the body handles glucose. The single report above is an anecdote — one person’s experience posted online — not a clinical trial. Clinical studies of tirzepatide show many people lose significant weight, but responses vary. Some people lose weight quickly, others more slowly, and some hardly at all. Timing matters: trials often measure results at 6 months to a year, and many patients need dose adjustments or additional lifestyle support. Other factors can blunt response: weight regained during pregnancy, hormonal changes after childbirth, breastfeeding, sleep loss, stress, certain medications, and individual biology. A 12-week stretch at a given dose is sometimes too short for big changes for some people. Why this matters: if you or someone you know is using Mounjaro and not seeing results, this is a common and important concern. It reminds us that these drugs help many people but are not guaranteed to produce the same outcome for everyone. If weight loss stalls, a doctor can reassess: check for other health conditions, review other medicines, consider dose changes or switching drugs, and add tailored dietary or behavioral support. For new parents, practical issues like disrupted sleep and increased calorie needs for breastfeeding can also affect results. Caveats and risks: do not change doses or stop/start tirzepatide without talking to your prescriber. Side effects commonly include nausea, vomiting, diarrhea, and constipation. Rare but serious risks can occur, and safety during pregnancy and breastfeeding brings extra caution — tirzepatide is not recommended during pregnancy; women typically stop it if they’re trying to conceive or discover pregnancy. Also, anecdotal reports can’t tell you why one person didn’t lose weight — only careful medical follow-up and sometimes tests can do that. Bottom line: one person not losing weight after 12 weeks on 15 mg of Mounjaro is not proof the drug won’t work for others or won’t work later; it’s a signal to check in with a clinician and review other possible reasons for the lack of effect.

Source: r/Mounjaro

Read full story

Back to Riding the pepTIDE